Peptide Mimotope Optimization

Zolbetuximab (IMAB362) is a chimeric monoclonal antibody that showed promising results in the treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma and is currently evaluated in phase III studies (Sahin et al. Ann. Oncol. 2021. PMID: 33610734).
Peptidic mimotopes for the ELISA-based detection of IMAB362 in biological samples were developed. Initial hits were identified using phage display and optimized with the help of structure-activity relationship analysis on peptide microarrays. The optimized peptides showed binding constants in the low nanomolar to picomolar range, an improvement by a factor of up to 30 compared to the initial hits. The best mimotope (apparent KD = 0.15 nM) was successfully used for the ELISA-based quantification of IMAB362 in samples from a mouse pharmacokinetic study.

product foto Mimotope optimization
product foto Mimotope optimization
product foto Mimotope optimization

References

References

Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362
Schnatbaum et al., Biotechnol. J. (2014)

Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362
Daneshdar et al, AppNote (2014)
Technologies
Partners

Partners

BioNTech AG, Mainz (M. Daneschdar, H.U. Schmoldt)
Johannes Gutenberg-University Mainz
TRON, Mainz
Ganymed Pharmaceuticals AG, Mainz
Loading...

Check our list of products, click and go.

Get a quote